Lack of KRAS and BRAF mutation in renal cell carcinoma.
Gattenlöhner
S
S
Etschmann
B
B
Riedmiller
H
H
Müller-Hermelink
H-K
HK
D000911:Antibodies, Monoclonal / Q000627:therapeutic use; D001707:Biopsy, Needle; D002292:Carcinoma, Renal Cell / Q000188:drug therapy / Q000235:genetics* / Q000473:pathology; D015331:Cohort Studies; D004252:DNA Mutational Analysis; D066246:ErbB Receptors / Q000627:therapeutic use; D005260:Female; D005500:Follow-Up Studies; D015972:Gene Expression Regulation, Neoplastic; D011905:Genes, ras / Q000187:drug effects / Q000235:genetics*; D006801:Humans; D007150:Immunohistochemistry; D007680:Kidney Neoplasms / Q000188:drug therapy / Q000235:genetics* / Q000473:pathology; D008297:Male; D009154:Mutation; D000077544:Panitumumab; D016133:Polymerase Chain Reaction; D048493:Proto-Oncogene Proteins B-raf / Q000187:drug effects / Q000235:genetics*; D018570:Risk Assessment; D012680:Sensitivity and Specificity
D000911:Antibodies, Monoclonal; D000077544:Panitumumab; D066246:ErbB Receptors; C482119:BRAF protein, human; D048493:Proto-Oncogene Proteins B-raf